Results 41 to 50 of about 720,445 (328)

Advocacy in Action: Leveraging the Power of Patient Voices to Impact Ovarian Cancer Outcomes in Canada

open access: yesCurrent Oncology, 2022
Prior to 1997, ovarian cancer (OC) was a ‘poor target’ for patient advocacy. At that time, there were only three OC researchers in Canada, little information available for women diagnosed, and no community of survivors existed.
Elisabeth Baugh   +4 more
doaj   +1 more source

The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance [PDF]

open access: yes, 2019
Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading cause of cancer-related deaths among women worldwide. The main reasons for this poor prognosis are late diagnosis; when the disease is already in an advanced stage ...
Berx, Geert   +3 more
core   +2 more sources

Ovarian and cervical cancer awareness: development of two validated measurement tools. [PDF]

open access: yes, 2011
The aim of the study was to develop and validate measures of awareness of symptoms and risk factors for ovarian and cervical cancer (Ovarian and Cervical Cancer Awareness Measures)
Corker, E   +7 more
core   +2 more sources

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma

open access: yesScientific Reports, 2023
Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor ...
Robert L. Hollis   +17 more
doaj   +1 more source

In Vitro Chemosensitivity Using the Histoculture Drug Response Assay in Human Epithelial Ovarian Cancer [PDF]

open access: yes, 2012
The choice of chemotherapeutic drugs to treat patients with epithelial ovarian cancer has not depended on individual patient characteristics. We have investigated the correlation between in vitro chemosensitivity, as determined by the histoculture drug ...
Kim, Dae-Yeon   +6 more
core   +1 more source

Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]

open access: yes, 2009
Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
B Stordal   +7 more
core   +2 more sources

BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers [PDF]

open access: yes, 2016
Background: The K3326X variant in BRCA2 (BRCA2*c.9976A>T; p.Lys3326*; rs11571833) has been found to be associated with small increased risks of breast cancer.
Agnarsson, Bjarni A.   +252 more
core   +1 more source

Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions

open access: yesNature Communications, 2019
OPCML is a tumour suppressor gene that is epigenetically silenced in ovarian cancer and is somatically mutated in various cancers. Here, the authors solve the X-ray crystal structure of OPCML and model clinically relevant mutations that could contribute ...
James R. Birtley   +17 more
doaj   +1 more source

LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma

open access: yesScientific Reports, 2023
Long interspersed element 1 (LINE-1) open reading frame 1 protein (ORF1p) expression is a common feature of many cancer types, including high-grade serous ovarian carcinoma (HGSOC).
Sho Sato   +19 more
doaj   +1 more source

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer [PDF]

open access: yes, 2015
Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours ...
Biglia, Nicoletta   +6 more
core   +3 more sources

Home - About - Disclaimer - Privacy